Mainz Biomed Q2 2025 Earnings Report

Mainz Biomed EPS Results

• Actual EPS: -$1.33
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Mainz Biomed Revenue Results

• Actual Revenue: $0.14 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Mainz Biomed Announcement Details

• Quarter: Q2 2025
• Date: 9/26/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Mainz Biomed (NASDAQ:MYNZ) AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer. ColoAlert® has received CE marking for commercialization in Europe and is part of Mainz Biomed’s strategy to address gaps in current screening programmes by offering an alternative to traditional colonoscopy and immunochemical fecal occult blood tests.

Founded as a spin-off from the Johannes Gutenberg University Mainz, Mainz Biomed has leveraged academic research in epigenetics to build a clinical pipeline focused on gastrointestinal cancers. The firm has established partnerships with clinical research centres and diagnostic laboratories across Europe, and it is conducting studies to support regulatory submissions in the United States. Through these collaborations, Mainz Biomed aims to validate its assays in diverse patient populations and support the integration of epigenetic testing into standard screening protocols.

Led by a management team with deep experience in biotechnology, molecular diagnostics and regulatory affairs, Mainz Biomed continues to expand its product portfolio and broaden its geographic footprint. The company is pursuing additional indications beyond colorectal cancer and is investing in research and development to refine its platform for the early detection of other tumor types. As it advances clinical validation and navigates regulatory pathways, Mainz Biomed seeks to establish itself as a leader in epigenetic diagnostics and preventive oncology.